Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant Plus Everolimus in ER-Positive, HER2-Negative Advanced Breast Cancer
NCT05306340Phase 3Active, not recruiting
- Sponsor
- Genentech
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Genentech. Started Aug 2022; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05306340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306340.